Suchergebnisse - "Rahman, Omar"

PubPharm (8)

1

Toxicity patterns associated with chemotherapy/immune checkpoint inhibitor combinations : a meta-analysis

enthalten in: Immunotherapy | 2019

von Abdel-Rahman, O.

2

Smoking and EGFR status may predict outcomes of advanced NSCLC treated with PD-(L)1 inhibitors beyond first line : A meta-analysis

enthalten in: The clinical respiratory journal | 2018

von Abdel-Rahman, O.

3

Evaluation of efficacy and safety of different pembrolizumab dose/schedules in treatment of non-small-cell lung cancer and melanoma : a systematic review

enthalten in: Immunotherapy | 2016

von Abdel-Rahman, O.

ErratumIn: Immunotherapy. 2017 Mar;9(4):373. - PMID 28303770

4

PD-L1 expression and outcome of advanced melanoma patients treated with anti-PD-1/PD-L1 agents : a meta-analysis

enthalten in: Immunotherapy | 2016

von Abdel-Rahman, O.

5

Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors : a meta-analysis

enthalten in: Therapeutic advances in respiratory disease | 2016

von Abdel-Rahman, O. | Fouad, M.

6

A network meta-analysis of the risk of immune-related renal toxicity in cancer patients treated with immune checkpoint inhibitors

enthalten in: Immunotherapy | 2016

von Abdel-Rahman, O. | Fouad, M.

7

Risk of endocrine complications in cancer patients treated with immune check point inhibitors : a meta-analysis

enthalten in: Future oncology (London, England) | 2016

von Abdel-Rahman, O. | ElHalawani, H. | Fouad, M.

8

Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors : a meta-analysis

enthalten in: Expert opinion on drug safety | 2015

von Abdel-Rahman, O. | ElHalawani, H. | Fouad, M.

1
[1]